SteadySharesSteadyShares
The market
MarketsDiscover
Follow the money
Smart MoneyPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Closed
SteadySharesMarketsDiscoverSmart MoneyMy WealthPoliticiansCryptoNews
/
DiscoverMRK.DE
HealthcareXetraEUR

Merck KGaA

€001234567890012345678900123456789.0012345678900123456789+4.5%
52w low (est.) €110.19€173.99 52w high (est.)
Peers
Market data
Market cap
€60.74B
52-week range
€100.70 – €148.65
Beta (vs market)
0.82
Sector
Healthcare
Valuation
P/E ratio
24.0x
DCF fair value
€68.56
Margin of safety
-50.3%
Forward P/E
16.1x
PEG ratio
2.76
Dividend yield
1.57%
Quality & efficiency
Moat score
60/100
Return on equity
8.5%
Profit margin
12.1%
Debt / equity
0.40
Growth & analysts
Revenue growth (YoY)
-2.8%
Analyst target
€145.86
Target upside
+5.7%
Analysts covering
14

About Merck KGaA

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.

Valuation

ValueGrowthProfitHealthIncome33QUALITY
Overall Rating
40
Reduce
Reduce
Moat Score60
DCF Intrinsic Value
€68.56-50.3% downside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
€60.74B
P/E Ratio
24.0
Dividend Yield
1.57%
Revenue Growth
-2.8%
Profit Margin
12.1%
ROE
8.5%
Debt / Equity
0.40
Beta
0.82
vs Healthcare sector:P/E 24 vs 28 · cheaperMoat 60 vs 7Yield 1.57% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · MRK.DE